Business Context and Reporting Period
Company: Alterity Therapeutics Limited
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of April 2020
Date Filed: April 22, 2020
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a regulatory event rather than a financial statement.
Material Changes
The primary material event disclosed is the receipt of temporary relief from NASDAQ regarding listing requirements. The filing does not detail specific financial changes compared to prior periods.
Guidance, Outlook, and Risks
- Regulatory Status: The company is seeking or has received temporary relief from NASDAQ (Item 99.1).
- Registration Statements: This Form 6-K is incorporated by reference into Registration Statement on Form S-8 (File No. 333-228671) and Form F-3 (Files No. 333-220886 and 333-231417).
- Management Commentary: No specific outlook or commentary on operations is provided in this text.
Investor Verification Checklist
- Verify the specific nature and duration of the NASDAQ temporary relief granted.
- Review the referenced Form S-8 and Form F-3 registration statements for details on capital raising or equity plans.
- Check subsequent filings for the company's compliance status with NASDAQ listing standards following this relief.
- Confirm if the temporary relief was a response to a specific financial metric deficiency (e.g., stock price or market cap).